GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther Oncolytics
Main Authors: Sette, Paola, Amankulor, Nduka, Li, Aofei, Marzulli, Marco, Leronni, Daniela, Zhang, Mingdi, Goins, William F., Kaur, Balveen, Bolyard, Chelsea, Cripe, Timothy P., Yu, Jianhua, Chiocca, E. Antonio, Glorioso, Joseph C., Grandi, Paola
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Gene & Cell Therapy 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6926261/
https://ncbi.nlm.nih.gov/pubmed/31890868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2019.10.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados